-
A study by the Rand Corp., a nonpartisan research organization, found that, across all drugs, U.S. prices were 2.78 times higher than the prices in 33 OECD countries. The gap was even larger for brand-name drugs.
-
Drugmakers offer copay assistance programs to patients, but insurers are tapping into those funds, not counting the amounts toward patient deductibles. That leads to unexpected charges. But the practice is under growing scrutiny.
-
Mary Mayhew, president and CEO of the Florida Hospital Association, said the group has over 100 hospitals that directly contract with Change Healthcare, the target of the cyberattack.
-
As national distributors and pharmacies restricted the flow of painkillers in response to the opioid crisis, Florida’s most popular grocer did the opposite, according to a Tampa Bay Times data analysis.
-
HHS issued a summary about a Jan. 12 discussion between Secretary of Health Xavier Becerra and Canadian Health Minister Mark Holland.
-
The governors square off in a first-of-its-kind debate Thursday. Let's compare the political rivals’ health care positions, showing how their policies helped — or hinder— the health of their states’ residents.
-
The company said that customers in College Station, Texas, can now get prescriptions delivered by a drone within an hour of placing their order.
-
To contain the opioid crisis, agencies have turned to technology to monitor prescription data. Experts have raised questions about how these systems work and worry about their accuracy and potential biases.
-
Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.
-
A new report by AARP found that the top 25 drugs — covered under Medicare Part D — have almost tripled in price since they first entered the market.